Growth factors
- What it does biologically
- Proteins that bind cell receptors and trigger responses such as cell division.
- Research
- Fibroblast study
The science behind Purified Amniotic Fluid, Wharton's Jelly, Muse Cells, and more.
Living-cell research
Muse stands for multilineage-differentiating stress-enduring. Researchers first described these adult cells in 2010 within human skin-fibroblast and bone-marrow cell populations. They can be isolated using the SSEA-3 surface marker and are notable for tolerating stressful conditions.
In laboratory and mouse experiments, individual Muse cells produced descendants with characteristics of the three major embryonic tissue lineages. Transplanted cells also entered damaged skin, muscle, and liver and expressed proteins characteristic of those tissues. These observations helped establish the research case for studying Muse cells as a defined living-cell preparation. Read the original discovery.
Early research in people
A small randomized trial evaluated an intravenous donor-derived Muse-cell preparation after ischemic stroke. At 12 weeks, 10 of 25 treated participants and 1 of 10 placebo participants could manage their own affairs with at most slight disability. One treated participant had a severe prolonged seizure reported as an adverse reaction. The study is an early clinical result for one defined preparation and use, not evidence that every cell-based product has the same effects. Review the randomized trial.
Birth-tissue fluid
Amniotic fluid is the liquid surrounding a developing baby during pregnancy. Purified amniotic fluid, or PAF, is made by processing donated fluid to remove unwanted material while retaining selected fluid components. Depending on collection, purification, and storage, a finished preparation may contain dissolved proteins, hyaluronic acid, and extracellular vesicles. See an analysis of processed birth-tissue products.
The phrase purified amniotic fluid describes a product category, not one universal composition. Processing determines what remains and in what concentration, so research on human amniotic fluid does not by itself establish the contents or clinical effect of every finished product.
Umbilical-cord tissue
Wharton's jelly is the soft connective tissue surrounding blood vessels in the umbilical cord. Its extracellular matrix, the material between its cells, contains collagen fibers and water-holding molecules. Processing can produce preparations that retain cells or preparations designed to retain the matrix after cells are removed.
Processing retains cells within the tissue matrix. Viability testing evaluates how many remain alive after processing and storage.
Processing removes cells while retaining parts of the surrounding tissue material. The method affects how much matrix remains and how well its structure is preserved.
Research examples: Wharton's jelly matrix and Wharton's jelly stromal cells.
Cell-to-cell communication
Cells release tiny membrane-bound particles called extracellular vesicles. These particles can carry proteins, lipids, and RNA. Some interact with receptors on another cell's surface; others can enter a receiving cell and deliver their contents.
Exosome has a narrower scientific meaning: a vesicle formed inside an endosome and then released. When a study establishes only a particle's size and surface markers, the more precise term is small extracellular vesicle. Read the MISEV2023 guidelines.
Human amniotic fluid contains extracellular vesicles, and processing may retain or concentrate them alongside dissolved proteins. That does not make every vesicle preparation identical: source material, isolation method, characterization, dose, and storage all matter. Explore amniotic-fluid vesicle proteins.
Blood-derived materials and procedures
Blood-based approaches are often discussed alongside regenerative science, but they use different starting material and mechanisms. PRP and PRF concentrate a patient's own platelets. Young-donor plasma provides another person's plasma. Therapeutic plasma exchange removes and replaces a patient's plasma.
Platelets are cell fragments that help stop bleeding and release proteins involved in clotting and tissue repair. PRP concentrates platelets in plasma. PRF holds platelets within a fibrin mesh that can be used as a clot or membrane.
A randomized facial-aging study found that participants rated texture and wrinkles more favorably on the PRP-treated cheek after six months, while dermatologist ratings of photographs found no significant difference. PRF has also been studied alongside periodontal surgery for gum recession. PRP facial study · PRF systematic review
A small study enrolled 18 people with mild-to-moderate Alzheimer's disease and tested weekly infusions of plasma from donors aged 18 to 30. It primarily evaluated safety, tolerability, and feasibility. No related serious adverse events occurred, although one participant stopped because of hives.
Its small group, short duration, and mixed design make it an early feasibility study, not a demonstration of rejuvenation in people. Read the 2019 clinical trial.
Therapeutic plasma exchange removes a patient's plasma, returns the blood cells, and replaces the removed volume with albumin-containing fluid or donor plasma. In antibody-driven diseases, removing plasma can lower circulating disease-causing antibodies. Clinical apheresis guidelines.
Alzheimer's research has tested plasma exchange with albumin replacement, sometimes with intravenous immunoglobulin. Aging research has also examined changes in blood-based biological-age measurements. Biomarker changes are not the same as demonstrated improvements in function, disease occurrence, or long-term health. AMBAR trial · 2025 biomarker trial